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Abstract
Introduction: Prothrombin Complex Concentrate (PCC) is a key treatment in the management of bleeding related
to Vitamin K antagonists (VKA). This study aimed to evaluate prospectively PCC use in patients with VKA-related
bleeding in view of the French guidelines published in 2008.
Methods: All consecutive patients with VKA-related bleeding treated with a 4-factor PCC (Octaplex®) were selected
in 33 French hospitals. Collected data included demographics, site and severity of bleeding, modalities of PCC
administration, International Normalized Ratio (INR) values before and after PCC administration, outcomes and
survival rate 15 days after infusion.
Results: Of 825 patients who received PCC between August 2008 and December 2010, 646 had severe bleeding.
The main haemorrhage sites were intracranial (43.7%) and abdominal (24.3%). Mean INR before PCC was 4.4 ± 1.9;
INR was unavailable in 12.5% of patients. The proportions of patients who received a PCC dose according to
guidelines were 15.8% in patients with initial INR 2-2.5, 41.5% in patients with INR 2.5-3, 40.8% in patients with INR
3-3.5, 26.9% in patients with INR > 3.5, and 63.5% of patients with unknown INR. Vitamin K was administered in
84.7% of patients. The infused dose of PCC did not vary with initial INR; the mean dose was 25.3 ± 9.8 IU/Kg. Rates
of controlled bleeding and target INR achievement were similar, regardless of whether or not patients were
receiving PCC doses as per the guidelines. No differences in INR after PCC treatment were observed, regardless of
whether or not vitamin K was administered. INR was first monitored after a mean time frame of 4.5 ± 5.6 hours
post PCC. The overall survival rate at 15 days after PCC infusion was 75.4% (65.1% in patients with intracranial
haemorrhage). A better prognosis was observed in patients reaching the target INR.
Conclusions: Severe bleeding related to VKA needs to be better managed, particularly regarding the PCC infused
dose, INR monitoring and administration of vitamin K. A dose of 25 IU/kg PCC appears to be efficacious in
achieving a target INR of 1.5. Further studies are required to assess whether adjusting PCC dose and/or better
management of INR would improve outcomes.
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Introduction
Vitamin K antagonists (VKAs) are oral anticoagulants
that inhibit liver production of vitamin K-dependent
coagulation factors, such as factors II, VII, IX, and X
and proteins C and S. Bleeding in patients treated with
VKA is the most serious iatrogenic complication, lead-
ing to more than 17,000 hospitalizations per year in
France (that is, 12% of hospitalizations related to adverse
events) [1]. Moreover, VKA causes 5,000 deaths per year
[2-6]. The incidence of bleeding associated with oral
anticoagulants is expected to increase over time as the
population ages.
Intracranial hemorrhage is the principal type of bleeding
related to oral anticoagulants, accounting for approxi-
mately 15% of all intracranial hemorrhages [7-9]. The
rates of intracranial hemorrhages range from 0.25% to
1.1% per year to about 2% when the international normal-
ized ratio (INR) exceeds 2 and rise dramatically thereafter
[10-14]. Concomitant use of antithrombotic treatments
doubles the risk of intracranial hemorrhage [10]. Intracra-
nial hemorrhages related to VKA have a high mortality
rate, approaching 50% at 1 month [7]. The prognosis of
patients with VKA-related intracranial hemorrhage is gen-
erally poor compared with that of patients with sponta-
neous intracranial hemorrhage. In these patients, the
hemorrhage is larger at baseline and hematoma expansion
may persist after admission [15-17]. Hematoma size is a
major predictor of mortality and worsening neurological
condition. Early and rapid INR correction is therefore cru-
cial in the management of these patients [18]. Coagulation
reversal should be initiated as soon as symptom onset
occurs to prevent hematoma expansion [16,19-21].
In July 2008, the French National Health Authority
(Haute Autorité de Santé) published guidelines for mana-
ging patients with bleeding complications related to oral
anticoagulants by elective or emergency surgery or other
invasive procedures [1]. In these guidelines, prothrombin
complex concentrate (PCC) was recommended for rapid
INR normalization (INR of less than 1.5) in patients with
VKA-related bleeding.
Previous published data showed that the management
of VKA-related intracranial hemorrhage was not in line
with current recommendations in European countries
[22]. In France, PCC remains under-used in the treat-
ment of severe hemorrhage and physicians do not always
follow the recommended dosage [23]. Efforts thus should
be made to follow recommendations in the choice of
indications, dosage, and coagulation monitoring.
Octaplex® (Octapharma, Lachen, Swizerland) is a
human plasma-derived four-factor PCC, including factors
II, VII, IX, and X, and has undergone detergent treatment
and nanofiltration for viral inactivation. This product also
contains proteins C and S, two natural factors limiting the
extension of the coagulation process [24].
We conducted a prospective observational study
(Optiplex study) between 2008 and 2010 to describe the
current use of PCC. The main objective was to assess
the current management of patients with severe bleed-
ing associated with VKA and treated with PCC.
Materials and methods
Patients
Optiplex was a multicenter prospective observational
study conducted in 33 French hospitals between August
2008 and December 2010. Patients were given the usual
care to manage bleeding related to VKA. Ethical approval
therefore was not sought, and informed consent was not
obtained. Data were collected anonymously. In each parti-
cipating center, PCC was stored in the central pharmacy
and delivered upon request, mainly to emergency depart-
ments or intensive care units. The patients included were
identified from the list of patients prescribed PCC at each
central pharmacy. Patients had to meet the following cri-
teria to be included in the study: they had to be at least 18
years old and treated with VKA and had to have received
PCC for spontaneous or traumatic hemorrhage or for the
management of increased bleeding risk before unplanned
surgery. Severe bleeding was defined as life-threatening or
organ-compromising bleeding, external bleeding uncon-
trolled with conventional measures, bleeding with hemo-
dynamic instability (systolic blood pressure of less than
90 mm Hg or systolic blood pressure decrease of at least
40 mm Hg or mean blood pressure of less than 65 mm
Hg or any signs of shock), or hemorrhage requiring urgent
surgery or red cell transfusion.
Collected data
Collected data included demographics, indication for
VKA therapy, and site and severity of bleeding. Concomi-
tant coagulation disorders such as disseminated intravas-
cular coagulation (DIC) syndrome or fibrinolysis and
history of heparin-induced thrombocytopenia were
reported. If transfusion was required, the type and
volume of product - red cells, platelet concentrates, and
fresh frozen plasma (FFP) - were reported. The Beyth
score was calculated by using the Outpatient Bleeding
Risk Index. One point was given for each of the follow-
ing: (a) age of 65 or more, (b) history of gastrointestinal
bleeding, (c) history of stroke, and (d) one or more
comorbid conditions (recent myocardial infarction, ane-
mia, renal impairment, or diabetes mellitus). The patient
was at low risk if the score was 0, moderate risk if the
score was 1 or 2, and high risk if the score was 3 or
more. The initial INR value, which was available before
infusion, was reported. A note was made whenever the
initial INR value was unavailable. Details concerning
PCC administration, including the time and dose of the
first administration, any subsequent administration, and
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simultaneous administration of vitamin K, were assessed.
INR values and results of blood testing within 24 hours
of PCC administration were collected. Clinical outcomes
such as bleeding control and INR normalization (target
INR of less than 1.5) were also evaluated. Outcomes at
day 15 after PCC infusion, including death, thromboem-
bolic events, and DIC, were assessed. Data on anticoagu-
lation treatments, VKA, or heparin in the 15 days
following PCC administration were collected.
Statistical analysis
Data were analyzed by using SAS 9.1 software (SAS Insti-
tute Inc., Cary, NC, USA). Categorical data were described
by frequency and percentages; continuous data were sum-
marized by their mean and standard deviation. Compari-
sons were assessed by using the analysis of variance,
Student t test, or Wilcoxon test for continuous variables
and the chi-squared or Fisher exact test for categorical
variables. Time from PCC administration to death was
estimated with the Kaplan-Meier method. Events were
censored at 15 days after PCC infusion. Hazard ratio and
two-sided 95% confidence interval were estimated from
univariate and multivariate Cox models. Comparisons
between strata were assessed with the log-rank test.
Results
In total, 825 patients (that is, 89% of patients who
received PCC during the study period) were included in
the analysis. Patients were admitted to emergency depart-
ments or intensive care units. Of these analyzed patients,
139 received PCC for the management of bleeding risk
prior to surgical or invasive intervention and 686 patients
for a bleeding episode (Figure 1).
In patients treated with PCC for bleeding, the mean age
was 78 years and 54% were men. Baseline characteristics
of patients with bleeding and distribution of bleeding
sites are shown in Tables 1 and 2, respectively. For 143
patients (22%), a concomitant anticoagulant therapy with
antiplatelets was reported. According to the Beyth score
[25], 59 patients (8.6%) were at high risk of bleeding. Of
these, 19 (32.2%) had a history of gastrointestinal bleed-
ing. Intracranial hemorrhages and acute gastrointestinal
bleeding were the main types of severe bleeding. Gastro-
intestinal bleeding and hematuria were more frequent in
patients treated with antiplatelet drugs (P = 0.041).
Criteria for severe bleeding in the 646 patients are shown
in Table 1. The INR was available before PCC adminis-
tration in 600 patients (87.5%) regardless of the severity
of bleeding. Table 3 shows the expected and infused
doses of PCC according to the initial value of INR and
the clinical outcomes. The mean value of INR was 4.4 ±
1.9 (median of 3.8) before PCC infusion. In patients with
intracranial hemorrhage (n = 300), the mean INR value
was 3.5 ± 1.5 (median of 3.2). The INR was considerably
increased, exceeding 3.5, in 337 patients (56.2% of
patients with documented INR). It was increased in the
remaining patients as follows: 33 (5.5%) had an INR
within 1.5 to 2, 89 (14.8%) within 2 to 2.5, 69 (11.5%)
within 2.5 to 3, and 72 (12.0%) within 3 to 3.5. The mean
infused PCC dose was 25.3 ± 9.7 IU/kg (range of 5.3 to
80). There was no difference between PCC infused doses
with regard to the initial INR value. For 226 patients
(32%), PCC was administered as a bolus dose (defined by
an infusion rate of greater than 8 mL/minute). Vitamin K
was administered in 576 patients (84.7%). No differences
were noted between the value of INR after PCC treat-
ment in the group that received vitamin K compared
with the group that did not receive vitamin K, regardless
of the time of INR measurement: H+30 minutes, H+60
minutes, H+6 hours, and H+24 hours. INR was first
monitored after a mean time frame of 4.5 ± 5.5 hours
after infusion and subsequently after a mean time of
11.9 ± 5.7 hours. Target INR (< 1.5) was reached in 452
patients (78.5%). In 163 patients, mean INR was 1.50 ±
0.58 one hour after PCC infusion. The proportion of
patients reaching target INR was similar regardless of the
initial INR value (P = 0.18). A comparison of the group
of ‘target INR achievers’ versus ‘INR non-achievers’
showed no differences concerning age, antiplatelet treat-
ment, location of hemorrhage, and administration of vita-
min K. Bleeding was completely controlled in 458
patients (79.1% of the overall population). Bleeding con-
trol was reported in 170 patients (85.4%) receiving a
lower PCC dose than expected, in 104 (77.6%) of the
patients receiving the expected PCC dose, and in
50 (70.4%) of the patients receiving a higher dose than
expected (P = 0.02). Table 4 shows the proportion of
patients who received PCC doses in compliance with
French recommendations. The estimated survival rate
within 15 days of PCC administration was 75.4% in the
overall population. No difference in survival was found
between groups with or without antiplatelet drugs. How-
ever, survival was found to be significantly impacted by
target INR achievement and bleeding control (P < 0.0001
for both) (Figures 2 and 3). Bleeding control and target
INR achievement were independent predictors of survi-
val: for bleeding control, hazard ratio (HR) was 0.28 (0.18
to 0.43) (P < 0.0001); for INR achievement, HR was 0.52
(0.34 to 0.81) (P < 0.004) (multivariate Cox model). In
patients with intracranial hemorrhage, the survival rate
was 65.1% at 15 days after infusion. Achievement of tar-
get INR (P = 0.02) and control of bleeding (P < 0.0001)
had a significant impact on the survival rate in this popu-
lation, whereas antiplatelet drugs had no impact. There
was no difference in the proportion of patients reaching
target INR regardless of concomitant vitamin K adminis-
tration (P = 0.89). However, bleeding control was signifi-
cantly higher in patients supplemented with vitamin K
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(81% versus 70% of patients not supplemented; P = 0.04).
Moreover, respecting the recommended dose had no
impact on survival (P = 0.16, log-rank test). In patients
followed for at least 14 days after PCC infusion, VKA was
resumed in 136 patients (26.4% of the overall population)
and in 21 patients (10.5%) with intracranial hemorrhage
(Table 5). After PCC infusion, four patients experienced
thromboembolic events: deep venous thrombosis was
diagnosed in three patients at six days, eight days, and 21
days, respectively, and stroke was diagnosed in one
patient at two days after PCC infusion. The stroke was
considered by the physician to be possibly related to PCC
infusion. One patient experienced DIC due to septic
shock at 21 days after PCC infusion.
Discussion
Here we report the characteristics and outcomes of
patients with VKA-related bleeding and treated with
PCC. Patients were recruited in emergency departments
and intensive care units. To the best of our knowledge,
this is the largest prospective ‘real life’ cohort reporting
the management of patients with severe bleeding related
to VKA.
In this study, severe bleeding sites were principally intra-
cranial, and this is consistent with previously reported
data. The most common risk factors for VKA-related
intracranial hemorrhage are age and high-intensity antic-
oagulation [26,27]. As expected, the mean patient age in
our study was 78 years, reflecting both the growing inci-
dence of atrial fibrillation and the higher risk of VKA-
related intracranial hemorrhage in older patients [28]. The
mean patient age, the high-intensity anticoagulation
(defined as an INR of greater than 3.5), the concomitant
use of antiplatelets (in 22% of patients) [10], and the sever-
ity of bleeding may explain the large proportion of patients
with intracranial hemorrhage.
Guidelines recommend PCC as the first choice or one
of the first choices for VKA effect reversal [29]. PCC is
Figure 1 Study flowchart. *Severe bleeding was defined as life-threatening or organ-compromising bleeding, external bleeding uncontrolled
with conventional measures, bleeding with hemodynamic instability (systolic blood pressure of less than 90 mm Hg or systolic blood pressure
decrease of at least 40 mm Hg or mean blood pressure of less than 65 mm Hg or any signs of shock), or hemorrhage requiring urgent surgery
or red cell transfusion. INR, international normalized ratio; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.
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able to normalize coagulation in a very short time, is
often preferred to FFP, and is considered by some to be
better tolerated [1]. Nevertheless, there are no prospec-
tive randomized controlled clinical trials comparing the
various VKA reversal strategies. Vitamin K administra-
tion is essential in the coagulopathy reversal strategy but
alone is not sufficient when rapid reversal is indicated
[14]. Current strategies derived from consensus-based
guidelines aim for rapid and safe coagulopathy correc-
tion [30,31]. Depending on whether INR is available,
patients should receive either a dose adjusted to INR
and body weight or a 25 IU/kg dose of factor IX. After
PCC administration, INR should be carefully monitored
to check whether the therapeutic objective (INR of less
than 1.5) has been fulfilled. A second PCC administra-
tion may be necessary [23].
Table 1 Characteristics of patients with bleeding (n = 686)
Demographic data
Age in years, mean ± SD 77.8 ± 10.8
Men, number (percentage) 368 (53.7)
Weight in kilograms, mean ± SD 72.0 ± 16.2
VKA indicationa, number (percentage)
Non-valvular atrial fibrillation 449 (65.5)
Venous thromboembolic disease 131 (19.1)
Mechanical heart valve 47 (6.9)
Not available 89 (13.0)
Other anticoagulant treatmentb, number (percentage)
Antiplatelet drugs 143 (22)
Outpatient bleeding risk index: Beyth score, number (percentage)
Mild risk 41 (6.0)
Intermediate risk 586 (85.4)
High risk 59 (8.6)
Criteria of severe bleedings (n = 646), number (percentage)
Life-threatening bleeding or organ-compromising bleeding 574 (88.3)
Hemodynamic instability 147 (21.4)
External bleeding uncontrolled with conventional measures 167 (26.3)
Need for red cell transfusion 217 (31.6)
Need for urgent surgery 162 (23.6)
aMore than one indication was possible; 89 values were missing; b36 values were missing. Outpatient bleeding risk index was calculated according to Beyth score
[29]. Hemodynamic instability was defined as the presence of one or more of the following criteria: systolic blood pressure (SBP) of less than 90 mm Hg, SBP
decrease of at least 40 mm Hg, mean blood pressure of less than 65 mm Hg, or any signs of shock. SD, standard deviation; VKA, vitamin K antagonist.











Intraocular or retro-orbital 4 (0.6)
Intraspinal 2 (0.3)
Unknown 37 (5.4)
Multiple sites of bleeding were observed in several patients: 22 patients with two sites, four patients with three sites, and one patient with four sites.
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In emergencies, the initial INR is often unavailable
before the administration of PCC. In our cohort, INR
was unavailable for 86 patients (12.5%), although 300
(43.7%) presented with life-threatening intracranial
hemorrhage. As the time frame between emergency
admission and PCC administration was not collected, we
cannot dismiss the possibility that PCC infusion had
been delayed until the INR results were available, particu-
larly in patients without hemodynamic instability. This
could explain the low proportion of patients whose INR
was unavailable. This time frame could also have an
impact on prognosis. It is widely accepted that the
shorter the delay for anticoagulation reversal, the better
the prognosis [22].
INR monitoring in this study was clearly not in line
with the recommendations. INR was first monitored with
a mean time frame exceeding 4 hours after PCC adminis-
tration, although INR monitoring is recommended at 30
minutes after infusion. Moreover, early INR monitoring
enables us to administer further PCC doses when the tar-
get INR is not achieved. This critical stage in monitoring
should be respected to improve INR normalization and
hemorrhage control.
Target INR is clearly defined as 1.5 in the French guide-
lines. However, some authors claim that the therapeutic
INR goal for intracranial hemorrhage should be not more
than 1.4 and preferably not more than 1.2 [14,32-35]. The
target INR was achieved in 452 patients (78.5%) in our
study. This result is in accordance with the level observed
in another series: 76.5% of patients with intracranial
hemorrhage achieved an INR of less than 1.5 in a recent
study by Desmettre and colleagues [36].
The proportion of patients reaching the target INR
(< 1.5) was not impacted by initial INR (P = 0.18),
although PCC was administered at lower doses than
expected in the majority of patients with significantly
increased INR (> 3.5). While PCC doses were expected to
increase with initial INR, infused doses were similar
regardless of the initial INR. Therefore, patients with an
initial INR ranging from 2 to 3 received a higher mean
dose than recommended, and 73.1% of patients with an
INR of greater than 3.5 received a lower mean dose than
recommended. PCC dosing thus was not always respected
in view of the French guidelines. Patients received a mean
PCC dose of 25 IU/kg, and initial INR did not seem to be
considered in the PCC dosing. However, PCC dosing had
no impact on the proportion of patients reaching the INR
target or on the proportion of patients with bleeding con-
trol. In patients with intracranial hemorrhage, PCC dosing
had no impact on survival, regardless of whether the
recommendations were followed. Further studies are
needed to assess whether adjusting the PCC dosage could
improve survival and clinical outcomes.
It has also been suggested that doses of less than 500 IU
could be appropriate if the INR is less than 5.0 [37]. This
could explain why doses that were lower than expected
resulted in similar outcomes. Furthermore, there is some
evidence that an individualized dosage based on initial












Expected PCC dose, IU/kg
Mean 10 20 25 > 30 25
Range 7.5-15 15-22.5 22.5-30
Infused PCC dose, IU/kg
Mean ± SD 24.9 ± 9.6 22.5 ± 6.9 27.1 ± 9.3 26.2 ± 10.2 25.2 ± 9.4
Target INR achievementa 40 (81.6) 37 (84.1) 30 (79.0) 171 (79.9) 46 (74.2)
Bleeding controlleda 38 (74.5) 34 (80.0) 27 (81.8) 175 (82.2) 50 (76.9)
Results are expressed as number (percentage) or as mean ± standard deviation (SD). The results are presented in patients with documented prothombin
complex concentrate (PCC) dose and initial international normalized ratio (INR) of at least 2 or unavailable INR (n = 479). aPercentages are calculated on the
number of patients with a documented response.
Table 4 Patients receiving prothombin complex concentrate dose in compliance with recommendations of the French
National Health Authority (Haute Autorité de Santé)










Patients with infused dose < expected dose 1 (1.8) 6 (11.3) 15 (30.6) 182 (73.1) 24 (34.7)
Patients with infused dose = expected dose 9 (15.8) 22 (41.5) 20 (40.8) 67 (26.9) 47 (65.3)
Patients with infused dose > expected dose 47 (82.5) 25 (47.2) 14 (28.6) 0 0
Results are expressed as number (percentage). Results are presented in patients with documented prothombin complex concentrate dose and initial international
normalized ratio (INR) of at least 2 or unknown INR (n = 479).
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INR and body weight results in a greater proportion of
patients who reach the target INR in comparison with the
standard dosage [38]. Nevertheless, the question of
whether to use an INR-based PCC dosage or a standar-
dized fixed dosage remains open to discussion [26,39].
It is essential to include vitamin K in the treatment regi-
men since PCC has transient effects [40]. In our cohort,
576 patients (84.7%) received concomitant vitamin K. In a
study including 18 patients with intracranial bleeding
requiring neurosurgical intervention and treated with PCC
(Kaskadil, LFB, Courtaboeuf, France). Vigue and collea-
gues [41] reported that INR was less than 1.5 within 6 to
12 hours after PCC infusion in 14 patients. The target INR
was not reached in the four remaining patients for whom
vitamin K had been omitted. In our cohort, no impact of
vitamin K was found on target INR achievement.
Patients presenting with intracranial hemorrhage gen-
erally have a poor prognosis compared with that of
patients with other bleeding sites. Survival rates were
75.4% in the overall population and 65.1% in patients
with intracranial hemorrhage. VKA-related intracranial
hemorrhages are reported to have a 50% mortality rate at
1 month [7]. The mortality rate of patients with intracra-
nial hemorrhage depends of the site of hemorrhage
[42,43], but unfortunately we did not collect details on
the type of intracranial hemorrhage.
As highlighted by Makris and Van Veen [44] in an edi-
torial introducing the results of a study by Imberti and
colleagues [45], the fact that a significant proportion of
patients died suggests that the PCC was appropriately
administered to those with life-threatening bleeding. In
our cohort, 52% of patients were older than 80, and old
age is known to be a predictor of poor prognosis. Rapid
anticoagulation reversal may lead to smaller hematoma
and shorter delays before neurosurgical interventions and
consequently to a better clinical outcome [46]. In our
study, we found that achievement of target INR and
bleeding control were strongly associated with survival.
Figure 2 Survival distribution function according to achievement of target international normalized ratio (INR). Full line: patients
reaching target INR. Dotted line: patients not reaching target INR. X-axis: Days after prothrombin complex concentrate infusion. Y-axis: Survival
distribution function. Estimated survival rates were 83.0% in patients reaching target INR and 65.5% in patients not reaching target INR (log-rank
P < 0.0001).
Figure 3 Survival distribution function according to bleeding control. Full line: Patients with controlled bleeding. Dotted line: Patients with
uncontrolled bleeding. X-axis: Days after prothrombin complex concentrate infusion. Y-axis: Survival distribution function. Estimated survival rates
were 84.5% in patients with controlled bleeding and 49.0% in patients with uncontrolled bleeding (log-rank P < 0.0001).
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Antiplatelet agents have been suspected to increase
hematoma growth and therefore to impair prognosis
[47], but the mortality rate in this study did not differ,
regardless of whether antiplatelets were used. The time
between symptom onset and INR normalization is likely
to be an important prognostic factor. Unfortunately, we
did not study the time from symptom onset to admission
or the time between admission and PCC administration,
since our study was designed to describe the modalities
of PCC use only. This time should be explored in a
further study.
The anticoagulation reversal in patients with underly-
ing thrombotic disease may be associated with a small
risk of thromboembolic events. Given the heterogeneity
in the composition of different formulations of PCC, the
risk of thrombogenicity may vary [11,28]. The presence
of procoagulant factors, such as factors II and X, and of
preactivated factors, such as factor VII, increases the risk
of thrombogenicity [48]. However, proteins C and S pre-
vent excessive coagulation [49]. Risk factors are also
related to the patient’s underlying condition. Throm-
boembolic events could be due to a combination of sev-
eral factors such as hypercorrection, hepatic dysfunction,
and induction of a prothrombogenic activation. In our
cohort, four out of 686 patients treated with PCC experi-
enced thromboembolism: one presented ischemic stroke
and three presented deep vein thrombosis. Stroke was
considered by the physician to be possibly related to
PCC. One further patient experienced DIC in a context
of septic shock and no less than 21 days after PCC infu-
sion. No patient experienced arterial thrombosis or
heparin-induced thrombocytopenia. These results are in
line with those of a meta-analysis (n = 460 patients) that
reported a low thrombotic risk with PCC (1% to 5%)
[50]. However, we acknowledge that thrombotic events
could occur a long time after PCC infusion. In a study of
46 patients with intracranial bleeding, Imberti and collea-
gues [45] reported that two patients experienced throm-
botic events 47 and 56 days after a three-factor PCC
administration, although the authors concluded that
these events were unlikely to be related to PCC
administration.
Finally, depending on VKA indication, the French
guidelines recommend stopping VKA or considering
resumption. For patients with intracranial hemorrhage
who have received VKA for non-valvular atrial fibrilla-
tion, VKA should be permanently stopped. However,
VKA was resumed in approximately 11% of these
patients in our study.
Our results have some limitations. We were interested
in the modalities of Octaplex® use and thus we did not
collect data on other types of PCC. The rate of throm-
botic events cannot be extrapolated to other types of
PCC since there is a great disparity in PCC composition,
particularly regarding proteins C and S and heparin. We
cannot claim that our data are exhaustive, despite care-
ful monitoring in each center. Some interesting data
were not collected, including variables known to impair
prognosis in intracranial hemorrhages, such as large
hematoma, infratentorial hemorrhage location, low
scores on the Glasgow Coma Scale, presence of intra-
ventricular blood, QTc prolongation on an electrocar-
diogram, and high serum glucose at admission [7].
Patients were followed for 15 days, which is probably
not long enough for older people and patients with
intracranial bleeding. A better indicator of outcome
would have been the outcome at hospital discharge.
Finally, the patients in our study were identified from
the list of patients with PCC prescription at the central
pharmacy of each participating hospital. Therefore,
patients with severe bleeding who did not receive PCC
were neither identified nor studied.




Venous thromboembolic disease Mechanical heart valve
Should definitively stop
taking VKA after ICH
Bridging anticoagulation period; VKA
resumption to be discussed
Bridging anticoagulation period;




Number 342 101 38 516
VKA
resumption
88 (25.7) 33 (32.7) 11 (28.9) 136 (26.4)
ICH
Number 137 31 16 199
VKA
resumption
15 (10.9) 4 (12.9) 4 (25.0) 21 (10.5)
Results are expressed as number (percentage). Results are presented in patients at day 15 after prothombin complex concentrate infusion. ICH, intracranial
hemorrhage; VKA, vitamin K antagonist.
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Conclusions
This large observational study showed that the manage-
ment of severe bleeding related to VKA should be
improved, particularly regarding PCC dosing, adequate
INR monitoring, and systematic concomitant administra-
tion of vitamin K. The PCC was administered for severe
bleeding related to VKA at a mean dose of 25 IU/kg, and
INR normalization was achieved in the majority of
patients. Bleeding control and target INR achievement
were independent predictors of survival. Further studies
are required to assess whether adjusting the PCC dose or
better management of INR or both would improve survi-
val rates.
Key messages
• In the VKA effect reversal, a mean dose of 25 IU/kg
PCC appears to be efficacious to achieve a target INR
of 1.5.
• Target INR achievement and bleeding control are
strong predictors for survival, regardless of hemor-
rhage site.
• In real-life conditions, management of severe
bleeding should be improved with respect to PCC
dosing and concomitant vitamin K administration.
• INR monitoring was not in line with French guide-
lines. The delay between PCC infusion and first INR
monitoring should be shortened.
• Bleeding control and target INR achievement were
independent predictors of survival.
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